10 Reasons Why Medicare Advantage Enrollment is Growing and Why It Matters
This issue briefs lays out 10 reasons why Medicare Advantage enrollment has been growing and why we can expect more growth in the years to come.
View the Latest: Medicare's Future
Filter
-
-
New Weight Loss Drugs Raise Issues of Coverage, Cost, Access and Equity
Event Date:EventNew weight loss drugs, such as Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide), could be transformative for people who struggle with obesity and obesity-related medical conditions, but there are major questions to consider related to insurance coverage, the cost of the drugs, and who has access. On August 4, three experts joined Larry Levitt, executive vice president for health policy at KFF, for a 45-minute “Health Wonk Shop” discussion about the…
-
KFF Health Tracking Poll March 2023: Public Doesn’t Want Politicians To Upend Popular Programs
FeatureLarge majorities of the public hold favorable views of Medicare and Medicaid. While most people worry about Medicare’s sustainability for the future, they also view the debate in Washington about Medicare cuts as largely politics.
-
What to Know about Medicare Spending and Financing
Issue BriefThis brief provides an overview of Medicare spending and financing, based on the most recent historical and projected data from the Medicare Trustees and the Congressional Budget Office (CBO). The brief highlights trends in Medicare spending and key drivers of spending growth, including higher enrollment, growth in health care costs, and increases in payments to Medicare Advantage plans.
-
Selected Out-of-Pocket Costs as a Share of the Average Social Security Benefit
FeatureMedicare premiums and cost sharing will account for an increasing share of Social Security benefits in the future, Medicare Trustees project.
-
The Growth in Share of Medicare Advantage Spending
FeatureEarlier this week, the Biden Administration announced the final Medicare Advantage rates for 2023, which are projected to result in an average increase in Medicare Advantage plan revenue of 8.5% compared to 2022 - the highest average expected increase in recent years. Payments to Medicare Advantage plans as a share of total Medicare spending on Part A and Part B services have increased from 26% in 2010 to 45% in 2020, and are expected to…
-
KFF Health Tracking Poll – October 2021: Home And Community Based Services And Seniors’ Health Care Needs
FeatureThe October KFF Health Tracking Poll explores experiences with unpaid caregiving, and favorability of expansion of home and community based services (HCBS). It also examines experiences with difficulty affording and putting of health care services among seniors, favorability of the ACA and experience with determining eligibility for lower cost insurance as part of the COVID relief package.
-
The Public Weighs In On Medicare Drug Negotiations
FeatureThis data note from the latest KFF Health Tracking Poll explores the public's views on Medicare drug price negotiation, including how arguments on both sides impact support and opposition; confidence in leaders to do the right thing on drug pricing; and experiences with prescription drug costs.
-
Large Majorities Across Parties Favor Allowing the Federal Government to Negotiate Drug Prices, Even After Hearing Common Arguments About It
News ReleaseMost of the Public Lacks Confidence that President Biden, Congressional Democrats or Republicans Will Do the Right Thing on Drug Prices Allowing the federal government to negotiate with drug companies to lower drug prices for Medicare beneficiaries and people enrolled in private plans – a key cost-saving proposal in the Democrats’ massive reconciliation bill – is favored by large majorities across political partisans, even after they hear arguments from both sides, a new KFF Health…
-
Potential Health Policy Administrative Actions Under President Biden
Issue BriefThis brief outlines the potential health policy actions that President Biden could take using executive authority, based on campaign pledges, and actions that would reverse or modify regulations or guidance issued by the Trump Administration.